This motivated us to investigate their plasma expression profiles and explore their potential as novel non-invasive diagnostic markers in DLBCL patients, their correlations with clinical data, and whether their pretreatment levels would predict patient responsiveness to R-CHOP therapy. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.